The study demonstrated a favorable safety profile, with the consolidated single-infusion regimen showing fewer infusion reactions compared to the reference regimen.

Phase 3 data support a lower age threshold for linaclotide, making it the first prescription therapy approved for functional constipation in patients ages 2 to 5.

The Agency will review supplemental data from AstraZeneca to address ODAC concerns regarding overall survival benefit, trial design interpretation, and cardiovascular safety.

Investigational oral substrate therapy BBP-418 demonstrated significant increases in alpha-dystroglycan glycosylation and improved ambulatory function in the phase 3 FORTIFY interim analysis.

The Trump administration has issued a directive shutting key US health research officials out of global discussions on virus outbreaks, according to CNN. Specifically, officials from the National ...

An ongoing phase 2 trial is assessing the efficacy of elunetirom for adults with bipolar depression taking a mood stabilizer.

The NIAID evaluates treatment and prevention options for a wide range of diseases and conditions, which includes what research gets funded and which vaccines are developed. HealthDay News — Dr Jeffery ...

A second opinion physician was held liable for an unnecessary hysterectomy despite a laboratory mix-up at the original facility.

For preschool-aged children presenting to the emergency department with moderate-to-severe acute wheezing, azithromycin does not lead to a reduction in the seve ...

Retatrutide demonstrated substantial dose-dependent improvements in waist circumference and crucial cardiovascular risk factors, including non-HDL-C, triglycerides, systolic blood pressure, and ...

A phase 3 study assessed pozdeutinurad compared with placebo in patients with gout who were inadequate responders to prior therapies.

Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.